Effects of orciprenaline (Alupent) in newborn infants of low birth weight.
D001724:Birth Weight; D002245:Carbon Dioxide / Q000097:blood; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007231:Infant, Newborn; D007275:Injections, Intravenous; D009921:Metaproterenol / Q000009:adverse effects / Q000494:pharmacology; D009539:Nicotinic Acids / Q000494:pharmacology / Q000627:therapeutic use; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D011674:Pulse; D012118:Resorcinols / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D012129:Respiratory Function Tests; D013806:Theophylline / Q000494:pharmacology / Q000627:therapeutic use
D009539:Nicotinic Acids; D012118:Resorcinols; D002245:Carbon Dioxide; D009921:Metaproterenol; D013806:Theophylline; D010100:Oxygen